Atai Life Sciences Nv (ATAI)
$1.98
Insights on Atai Life Sciences Nv
Decreasing Revenue
Revenue is down for the last 3 quarters, 172.0K → 18.0K (in $), with an average decrease of 64.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 44.24M → -18.29M (in $), with an average decrease of 141.3% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 44.3% return, outperforming this stock by 34.0%
Performance
- $1.98$2.19$1.98
0.0%
Downside
Day's Volatility :9.59%
Upside
9.59%
- $1.02$2.85$1.98
48.48%
Downside
52 Weeks Volatility :64.21%
Upside
30.53%
Returns
| Period | Atai Life Sciences Nv | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 19.44% | -0.5% | 0.0% |
6 Months | 62.88% | 5.9% | 0.0% |
1 Year | 10.26% | 3.1% | -1.9% |
3 Years | -88.95% | 14.2% | -21.8% |
Highlights
Market Capitalization | 346.2M |
Book Value | $1.46 |
Earnings Per Share (EPS) | -0.25 |
Wall Street Target Price | 10.68 |
Profit Margin | 0.0% |
Operating Margin TTM | -186483.33% |
Return On Assets TTM | -25.52% |
Return On Equity TTM | -17.21% |
Revenue TTM | 314.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -52.6% |
Gross Profit TTM | 233.0K |
EBITDA | -122.0M |
Diluted Eps TTM | -0.25 |
Quarterly Earnings Growth YOY | -0.97 |
EPS Estimate Current Year | -0.77 |
EPS Estimate Next Year | -0.77 |
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Next Quarter | -0.17 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 439.39%
Technicals Summary
Sell
Neutral
Buy
Atai Life Sciences Nv is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Atai Life Sciences Nv | 28.74% | 62.88% | 10.26% | -88.95% | -88.95% |
 Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
 Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
 Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
 Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Atai Life Sciences Nv | NA | NA | NA | -0.77 | -0.17 | -0.26 | NA | 1.46 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Atai Life Sciences Nv | Buy | $346.2M | -88.95% | NA | 0.0% |
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
Institutional Holdings
Morgan Stanley - Brokerage Accounts
1.90%BlackRock Inc
0.82%Marshall Wace Asset Management Ltd
0.47%Millennium Management LLC
0.46%Brown University
0.43%Mirae Asset Global Investments (Korea) Co Ltd
0.38%
Corporate Announcements
Atai Life Sciences Nv Earnings
Atai Life Sciences Nv’s price-to-earnings ratio stands at None
Read More
Company Information
who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.
Organization | Atai Life Sciences Nv |
Employees | 83 |
CEO | Mr. Christian Angermayer |
Industry | Commercial Services |
